ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations
Friday, May 12, 2017
Submitted by
Source
Source Name: Circulation Research
A short and readable commentary on monoclonal antibodies and dyslipidaemias, particularly on FOURIER, SPIRE and ODYSSEY trials
Printer-friendly
